




We will begin momentarily at 2pm ET



Slides available now! Recordings will be available to ACS members after one week. www.acs.org/acswebinars

Contact ACS Webinars ® at acswebinars@acs.org







Have you discovered the missing element?



www.acs.org/2joinACS

Find the many benefits of ACS membership!



Hoping to inspires collaborations between researchers designing the next-generation of engineered nanomaterial-based technologies and those with the experimental and computational tools to probe the critical molecular interactions at the nano/bio interface.

http://pubs.acs.org/page/virtual_issue/nanotoxicology





Benefits of ACS Membership



Chemical & Engineering News (C&EN) The preeminent weekly news source.



NEW! Free Access to ACS Presentations on Demand[®] ACS Member only access to over 1,000 presentation recordings from recent ACS meetings and select events.



NEW! ACS Career Navigator Your source for leadership development, professional education, career services, and much more.

www.acs.org/2joinACS





Be a featured fan on an upcoming webinar! Write to us @ acswebinars@acs.org







Learn from the best and brightest minds in chemistry! Hundreds of webinars presented by subject matter experts in the chemical enterprise.

Recordings are available to current ACS members one week after the Live broadcast date.

Broadcasts of ACS Webinars[®] continue to be available to the general public LIVE every Thursday at 2pm ET!

www.acs.org/acswebinars

Upcoming ACS Webinars[®] www.acs.org/acswebinars





Thursday, October 1, 2015 "Predicting Nobel: The Who and Why of the Next Chemistry Nobel Prize Winner"

Philip Ball, Science Writer, Chemistry World Paul Bracher, Professor, St. Louis University and Blogger, ChemBark Jillian Buriak, Professor, University of Alberta and Editor-in-Chief, Chemistry of Materials Lauren Wolf, Asst. Managing Editor, Chemical & Engineering News Matt Davenport, Associate Editor, Chemical & Engineering News Co-produced with Chemical and Engineering News



Thursday, October 15, 2015

"The Material World of Color: Chemical Characterization of Pigments in Art"

Barbara Berrie, Head of Scientific Research, National Gallery of Art

Contact ACS Webinars ® at acswebinars@acs.org

AAPSCLEARNING



AAPS Preformulation 101

Preformulation in Drug Discovery and Development eLearning Series

Lecture 1: Preformulation and Biopharmaceutical Considerations in Drug Product Design and Development

Lecture 2: Drug Substance Physical Form Selection

Lecture 3: Drug Substance Physical Form Characterization

Lecture 4: Solubility: General Principles and Practical Considerations

Lecture 5: Dissolution and its Role in Solid Oral Dosage Form Development

Lecture 6: Biopharmaceutic Considerations

Lecture 7: Chemical Stability Assessment in Preformulation

Lecture 8: Excipient Compatibility Studies

Lecture 9: Impact of Material Properties on Formulation Development

Lecture 10: Prototype Formulations Screening and Characterization

NEW eCourse Available NOW!

Visit www.aaps.org/PF101 for more information.

Join the ACS Division of Medicinal Chemistry Today!





For \$25 (\$10 for students), You Will Receive:

- A free copy of our annual medicinal chemistry review volume (over 600 pages, \$160 retail price)
- · Abstracts of MEDI programming at national meetings
- Access to student travel grants and fellowships

Find out more about the ACS MEDI Division! www.acsmedchem.org


		#ACSWebinars Co-produced by sion of Medicinal Chemistry sociation of Pharmaceutical Scientists (AAPS)				
Module 1: I	mproving Drug Design Efficiency and Efficacy					
Jan 29	Designing Better Drug Candidates	Dr. Paul Leeson				
Feb 26	Strategies to Improve Solubility of Drug Candidates	Dr. Michael Walker				
Module 2: A	Module 2: Activity/Potency Screening for Drug Lead & Candidate Optimization					
Mar 19	Fragment-Based Drug Design Strategies	Dr. Dan Erlanson				
April 30	Screening Strategies	Dr. David Swinney				
May 28	PAINS (Pan-Assay Interference Compounds)	Dr. Jonathan Baell				
June 25	Positron Emission Tomography (PET) Labeling in Drug Discovery & Development	Dr. Lei Zhang				
July 30	X-Ray Crystallography in Drug Discovery	Dr. Jon Mason & Dr. Miles Congreve				
Module 3: E	Enabling Drug Discovery					
Aug 27	Choices and Trends in Solid Dosage Form Section	Dr. Scott Trzaska & Dr. Ron Smith				
Sept 24	Delivery Options to Support Dose Escalation in Preclinical Toxicology and Pharmacodynamic Activity Studies	Dr. Evan Thackaberry				
Module 4: I	Pharmacokinetics					
Oct 29	Pharmacokinetic Considerations in Drug Design and Development	Dr. Punit Marathe				
Nov 19	Prodrugs in Drug Discovery	Dr. John Higgins				

Join us October 29, 2015 for the 10th Session!



13

14



www.acs.org/content/acs/en/events/upcoming-acs-webinars/drug-design-2015.html



Delivery Options to Support Dose Escalation in Nonclinical Toxicology and Pharmacodynamic Activity Studies



Evan A. Thackaberry, Ph.D., D.A.B.T. Safety Assessment Genentech South San Francisco, CA thackabe@gene.com



9

Outline

The Critical attributes of a nonclinical formulation

- •What are we dosing and why?
- •What do we need from our nonclinical formulations?
- Typical industry use

• How the requirements for nonclinical formulations change over the lifespan of a drug development program.


- Phase-appropriate formulation selection
- •Case studies of formulation-related effects

• The key differences between preclinical and clinical formulations.

- •How are they different?
- •Can we use nonclinical studies to "qualify" new formulations?



Formulation Support is Critical for in vivo Studies











Why are the dose levels so high in nonclinical toxicology studies?

- To identify and characterize target organ toxicity
- To establish safety factors for the clinic
- To define the maximum tolerated dose (MTD)
- In order to meet health authority expectations
- All of the above





Genentech A Member of the Roche Group



All Components of a Formulation may have Biologic Effects

- API
 - PK, efficacy, and toxicity



- Effects PK (therefore efficacy & toxicity), may cause toxicity in rare circumstances
- Vehicles
 - Effects PK (therefore efficacy and toxicity), may cause toxicity on their own
- Impurities
 - Rarely impact PK or efficacy, but can cause toxicity if levels are high enough




H₃C





Basic Nonclinical Formulation Requirements



Do We Really Have to Dose THAT High?

- In order to provide a useful human risk assessment in support of clinical trials, the toxicity profile of a drug must be characterized
 - This is the toxicologist's job!
- Regulatory guidances (ICH M3) define the acceptable maximal dose levels
 - Maximum tolerated dose (MTD) animals cannot tolerate higher doses
 - Maximal feasible dose (MFD) can't physically dose any higher
 - · Plateau in exposure absorption-limited compounds
 - >50X the efficacious clinical exposure can change based on clinical data
 - 1000 mg/kg or 2000 mg/kg for clinical doses above 1 g



Route of Administration for Toxicology Studies

- Most routes Intravenous, subcutaneous, dermal, intravitreal, etc...
 - · Use the clinical formulation in all toxicity testing
 - Bridging studies may be required to support formulation changes
- Oral drugs
 - No need to use the clinical formulation
 - Oral gavage is generally used, but capsule dosing and dietary administration may be used as well
 - Key is to achieve high exposures in order to define the safety profile of the drug





What types of formulations are most commonly used for nonclinical safety studies with novel oral drugs?


- Aqueous solutions
- Simple suspensions
- Lipid-based formulations
- Solvent formulations
- Solid dispersions







What Vehicles are Most Commonly Used in Oral GLP Studies Across the Industry? A) Method of Oral Administration Review of Oral Nonclinical Formulation



Conclusions from Survey of Successful Preclinical Formulations

Method of Oral Administration

- Oral Gavage is used in vast majority of oral safety studies
- Many programs used multiple dose administration paradigms
- Capsule dosing generally limited to dog studies
- Dietary studies limited to chronic rodent (generally, rat) studies

Oral Gavage formulations


- Suspension agent (methylcellulose/gums) +/- surfactant (tween/SDS) used on >70% of all NDAs
- Many programs used multiple oral gavage formulations
- Formulations with potential for intolerability or biomarker effects used less frequently (lipid-based, HPBCD), or in subchronic (<1 mo) studies only




13

* Total = NCE 118 NDAs. Source: Thackaberry, 2013

Methods of Oral Administration




Oral Gavage Formulations



Critical Attributes & Industry Use: Key Messages


- There are no "inactive" or "nontoxic" vehicles or formulations. All vehicles have biologic effects at high doses.
- Vehicle concentration, dose volume, study duration, route of administration, species, and study endpoints will determine the acceptability of the formulation.
- In some cases, biological effects may be tolerated, as long as these effects don't interfere with the study endpoints.
- Most sponsors use simple suspension formulations, with or without surfactants for nonclinical oral gavage studies.





Formulation Requirements Depend on Study Design/Goals

- 1. Produces adequate exposure to the API
- 2. Allows for technically feasible dose administration
- 3. Allows for sufficient homogeneity and stability
- 4. Tolerated by the nonclinical species under the conditions of the study
- Does not interfere with the ability to interpret the key endpoints of the study



Genentech

Phase-Appropriate Formulation Strategy

Formulation strategy should take into account the current stage of a program

- Maximize flexibility for early stage lead optimization
 - · Solvent-based platform formulation for pk screening
 - Grossly tolerated formulations that maximize exposure for efficacy studies
- Transition to GLP-friendly formulations with lead molecules
 - Aqueous solutions, suspensions or nanosuspensions, enabling formulations if needed
 - Avoid bridging pk work or timeline delays due to formulation switches

• If needed, switch to acceptable formulations for chronic tox/carcinogenicity

- Suspensions, solid dispersions, nanosuspensions
- May not be required for <u>1st line immediately life-threatening</u> oncology indications





What Adverse Effects Might My Vehicle Produce in Non-Clinical Toxicology Studies?

- Acute Toxicity
- · Poor Tolerability
- Repeat Dose Toxicity
- Repeat Dose Tolerability Issues
- Biochemical/Metabolic Alterations
- Interference with MS Bioanalysis





Examples – Acute Toxicity/Tolerability Issues

Overt Toxicity

· Most often seen with i.v. vehicles

• Intoxication (solvents such as propylene glycol, DMSO, ethanol, glycerol, etc...)

· Generally don't see significant end-organ toxicity

Tolerability

• Emesis - Often seen with lipids, particularly medium chain triglycerides in large animals only

- · Diarrhea Lipids, anti-foaming agents, surfactants
- Anaphylaxis Non-ionic surfactants (iv administration on dogs)





Case Study: Toxicity/Tolerability of IV Solvents in Mice

Solvent	Published LD ₅₀	MTD	NOEL	% of a 5 mL/kg dose volume at MTD
Diethylacetamide	2.3-3.2 g/kg	1.4 g/kg	468 mg/kg	30%
Dimethylsulfoxide	3.8-7.6 g/kg	2.2 g/kg	1.6 g/kg	40%
Ethanol	1.6-4.3 g/kg	986 mg/kg	197 mg/kg	25%
N-Methylpyrrolidine	54-3600 mg/kg!	1.3 g/kg	257 mg/kg	25%
Propylene glycol	5.0-8.6 g/kg	1.5 g/kg	1 g/kg	30%
PEG 400	8.6-9.7 g/kg	4.5 g/kg	1.7 g/kg	80%

Conclusions:

- LD₅₀'s aren't very helpful in setting a tolerated vehicle dose
- NOELs (required for studies with tox endpoints) are often much lower than MTDs (possible doses for PK studies).
- Avoiding vehicle-related tolerability issues with new formulations can be a problem in early research, particularly in PK screens – could this be mistaken for a compound-related effect?



Sources: TOXNET & Thackaberry et al (2014)



Examples - Repeat Dose Toxicity Issues

• Repeat dose Toxicity

- Hepatotoxicity Hydroxyopropyl-beta-cyclodextrin (HPBCD), Captisol, Ethanol
- Renal Toxicity PEG400, HPBCD, Captisol, Poloxamer 188
- GI Toxicity Sodium dodecyl sulfate (SDS)
- Ocular Toxicity Dimethylsulfoxide (DMSO)

Repeat Dose Tolerability

• Repeated exposure to some lipid formulations with "bad taste" leads to animal struggling and misdosing/aspiration

• Cyclodextrins are not tolerated by rabbits (interfere with normal GI function?)



"Can you check my liver? I just returned from a Gordon Conference"



Genentech A Member of the Roche Group

Case Study: HPBCD Impact on Critical Biomarkers of Toxicity

· Study Design in Rats


- 3 mo of daily dosing at 500 & 1000 mg/kg (10 & 20%)
- Clinical Pathology evaluated on study weeks 4 & 12


Results

- Dose- and Duration-dependent elevation of serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT).
- AST and ALT are common biomarkers of hepatic damage
- No other evidence of liver toxicity (clinical pathology & histopathology)

Conclusion

- Apparent hepatic toxicity
- Effects appear to be minimal
- Impact on critical markers of hepatic damage will limit usefulness as a nonclinical formulations







Source: Thackaberry et al, 2010

Examples – Metabolic/Biochemical Issues

Dramatic Shifts in Normal Metabolic Function

•Chronic administration of lipids alters normal lipid metabolism, tumor incidence, & survival •High dose phosphate buffers alters normal phosphate metabolism, can lead to bone/renal toxicity

· Potential Interaction with drug metabolism, distribution, or excretion

Propylene glycol & PEG400 are excreted entirely by the kidneys – excretion may be altered by (or alter) renal effects of NCE
Non-ionic surfactants inhibit CYP3A4 & Pgp in vitro (in vivo significance unknown)

•Anti Oxidants (Vitamin E TPGS) inhibit normal mechanisms of toxicity

•Vehicles which interfere with Mass Spec Performance


All PEGs (including PEG 400)
High Dose Tween 80
Cremophor EL
Solutol HS 15
Labrosol








<u>Case Study</u>: Effects of Chronic Administration of Corn Oil* on Metabolism & Tumor Incidence in Rats





The Toxicologist's Perspective on Formulation Selection

Study Requirements

- Well tolerated
- Achieve adequate exposure

 No vehicle-related toxicities or effects which can not be segregated from NCE effects, or which might inhibit our ability to interpret the study data



Molecule/Program Requirements

"Take a few capsules each morning before you weigh yourself. They're filled with helium."

 Use across all possible study durations (including chronic) and species. If not, develop a distinct formulation for chronic tox

- Limit complexity due to formulation changes or unproven vehicles



25



Audience Survey Question

If we dosed patients/volunteers at the same <u>volume</u> as a typical oral nonclinical safety study, what approximate volume would they be asked to drink?

- 1 mL
- 5 mL
- 35 mL
- 350 mL
- 3 L



41

Nonclinical vs. Clinical Formulations for Oral Drugs

- For oral drugs, nonclinical and clinical formulations are typically distinct
- While the FDA regulates clinical excipients, there are no guidances dictating nonclinical formulation selection
 - · Allows for more flexibility
 - Can lead to formulation-related issues on nonclinical studies
 - Makes qualifying novel excipients for the clinic more difficult



"Your prescription is cheaper if you buy it in bulk."



Genentech A Member of the Roche Group

Oral Dose Volume and Vehicle Dose are Much Higher in Nonclinical Studies

- Standard nonclinical dose volumes are much greater than the volume used in the clinic
 - · Allows for higher doses of drug
 - Produces higher vehicle doses
 - Clinical excipient concentration (%) is not useful in assessing nonclinical tolerability
- Doses used in non-clinical toxicology studies are generally much higher than those used in the clinic
 - For non-oncology indications, generally 25-100X
 - Vehicle doses are much higher as well

Dose Volume					
Species	Dose Volume				
Rat	3.5 mL				
Dog	50 mL				
Human	350 mL				
*Assumes a 5 ml /kg doso					

*Assumes a 5 mL/kg dose volume in a normal adult animal

Vehicle Dose

Vehicle %	Vehicle Dose			
1%	~50 mg/kg/day			
10%	~500 mg/kg/day			
50%	~2.5 g/kg/day			
*Assumes a 5 ml /kg dose volume				


Genentech

Exposure is used to Bridge Nonclinical and Clinical Safety Data

Establish plasma exposure (AUC and C_{max}) to API in nonclinical safety studies.

28

Compare to predicted clinical exposure (safety factors or exposure multiples) or efficacious dose (therapeutic index)



* Key assumption is that %F & CI are likely to be different between nonclinical species and human, regardless of formulation





Qualification of Novel Excipients

- The FDA requires a similar battery of studies to qualify a new clinical excipient as would be required for a new non-oncology drug (FDA, 2005)
- However the distinct composition of the nonclinical formulation for oral drugs means these new excipients are not always tested along side the drug
- There is no mechanism for gaining approval for a new excipient other than as part of a NDA/BLA
- If a novel excipient is required for your drug, it is best to identify the issue early and include it in your nonclinical tox studies, even with oral drugs







Formulation Strategy: Key Messages

- Phase-appropriate formulation strategy allows for maximum flexibility in early in vivo studies while anticipating the need for "clean" formulations in GLP toxicology studies.
- Many common vehicles may have unwanted effects that could impact the interpretation of a toxicology study, particularly in chronic studies.
- The nonclinical and clinical formulations are distinct. Exposure is used to bridge the safety data.
- Novel excipients require a similar nonclinical testing paradigm to novel drugs.







References & Resources

- E.A. Thackaberry, et al (2014) Solvent Based Formulations for Intravenous Mouse Pharmacokinetic Studies: Tolerability and Recommended Solvent Dose Limits. *Xenobiotica* 44(3):235-241
- E.A. Thackaberry. (2013) Vehicle Selection for Oral Safety Studies. Expert Opinion in Drug Metabolism and Toxicology 9(12):1635-46
- B.P. Enright et al (2010) Assessment of Hydroxypropyl Methylcellulose, Propylene Glycol, Polysorbate 80, and Hydroxypropyl-Beta-Cyclodextrin for use in Developmental and Reproductive Toxicology Studies. *Birth Defects Research Part B. Developmental and Reproductive Toxicology* 89(6):504-516
- E.A. Thackaberry, et al (2010) Comprehensive Investigation of Hydroxypropyl Methylcellulose, Propylene Glycol, Polysorbate 80, and Hydroxypropyl-Beta-Cyclodextrin for use in General Toxicology Studies. *Toxicological Sciences*, 117(2): 485-492
- International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH, 2009a) Guidance for nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals (M3). Available at: http://www.ich.extent.com/is/action/is/acti

http://www.ich.org/fileadmin/Public Web Site/ICH Products/Guidelines/Multidisciplinary/M3 R2/Step4/M3 R2 Guideline. pdf

- S. Gad, et al. Nonclinical vehicle use in studies by multiple routes in multiple species. Int J Toxicology 2006;25(6):499-521
- Food and Drug Administration (2005) Guidance for industry: Nonclinical studies for the safety evaluation of pharmaceutical excipients. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM079250.pdf
- National Toxicology Program (NTP, 1994). Comparative Toxicology Studies of Corn Oil, Safflower Oil, and Tricaprylin (CASRNs 8001-30-7, 8001-23-8, and 538-23-8) in Male F344/N Rats as Vehicles for Gavage. National Toxicology Program Technical Report Series 426:311

Genentech






This session of the 2015 DDDS is being sponsored by Chemical Research in Toxicology

Join us October 29, 2015 for the 10th Session!





www.acs.org/content/acs/en/events/upcoming-acs-webinars/drug-design-2015.html

Upcoming ACS Webinars[®] www.acs.org/acswebinars





Thursday, October 1, 2015

"**Predicting Nobel:** The Who and Why of the Next Chemistry Nobel Prize Winner"

Philip Ball, Science Writer, Chemistry World Paul Bracher, Professor, St. Louis University and Blogger, ChemBark Jillian Buriak, Professor, University of Alberta and Editor-in-Chief, Chemistry of Materials Lauren Wolf, Asst. Managing Editor, Chemical & Engineering News Matt Davenport, Associate Editor, Chemical & Engineering News Co-produced with Chemical and Engineering News



Thursday, October 15, 2015

"The Material World of Color: Chemical Characterization of Pigments in Art"

Barbara Berrie, Head of Scientific Research, National Gallery of Art

Contact ACS Webinars ® at acswebinars@acs.org

50



Hoping to inspires collaborations between researchers designing the next-generation of engineered nanomaterial-based technologies and those with the experimental and computational tools to probe the critical molecular interactions at the nano/bio interface.

http://pubs.acs.org/page/virtual_issue/nanotoxicology



This session of the 2015 DDDS is being sponsored by Chemical Research in Toxicology

Join the ACS Division of Medicinal Chemistry Today!





For \$25 (\$10 for students), You Will Receive:

- A free copy of our annual medicinal chemistry review volume (over 600 pages, \$160 retail price)
- · Abstracts of MEDI programming at national meetings
- Access to student travel grants and fellowships

Find out more about the ACS MEDI Division! www.acsmedchem.org

AAPS@LEARNING



Preformulation in Drug Discovery and Development eLearning Series

Lecture 1: Preformulation and Biopharmaceutical Considerations in Drug Product Design and Development

Lecture 2: Drug Substance Physical Form Selection

Lecture 3: Drug Substance Physical Form Characterization

Lecture 4: Solubility: General Principles and Practical Considerations

Lecture 5: Dissolution and its Role in Solid Oral Dosage Form Development

Lecture 6: Biopharmaceutic Considerations

Lecture 7: Chemical Stability Assessment in Preformulation

Lecture 8: Excipient Compatibility Studies

Lecture 9: Impact of Material Properties on Formulation Development

Lecture 10: Prototype Formulations Screening and Characterization

NEW eCourse Available NOW!

Visit www.aaps.org/PF101 for more information.



53



Be a featured fan on an upcoming webinar! Write to us @ acswebinars@acs.org







Benefits of ACS Membership



Chemical & Engineering News (C&EN) The preeminent weekly news source.



NEW! Free Access to ACS Presentations on Demand[®] ACS Member only access to over 1,000 presentation recordings from recent ACS meetings and select events.



NEW! ACS Career Navigator Your source for leadership development, professional education, career services, and much more.

www.acs.org/2joinACS





57

58

ACS Webinars[®] does not endorse any products or services. The views expressed in this presentation are those of the presenter and do not necessarily reflect the views or policies of the American Chemical Society.



Contact ACS Webinars ® at acswebinars@acs.org

		#ACSWebinars Co-produced by sion of Medicinal Chemistry sociation of Pharmaceutical Scientists (AAPS)
Module 1: I	mproving Drug Design Efficiency and Efficacy	
Jan 29	Designing Better Drug Candidates	Dr. Paul Leeson
Feb 26	Strategies to Improve Solubility of Drug Candidates	Dr. Michael Walker
Module 2: A	Activity/Potency Screening for Drug Lead & Candidate Opti	imization
Mar 19	Fragment-Based Drug Design Strategies	Dr. Dan Erlanson
April 30	Screening Strategies	Dr. David Swinney
May 28	PAINS (Pan-Assay Interference Compounds)	Dr. Jonathan Baell
June 25	Positron Emission Tomography (PET) Labeling in Drug Discovery & Development	Dr. Lei Zhang
July 30	X-Ray Crystallography in Drug Discovery	Dr. Jon Mason & Dr. Miles Congreve
Module 3: E	Enabling Drug Discovery	
Aug 27	Choices and Trends in Solid Dosage Form Section	Dr. Scott Trzaska & Dr. Ron Smith
Sept 24	Delivery Options to Support Dose Escalation in Preclinical Toxicology and Pharmacodynamic Activity Studies	Dr. Evan Thackaberry
Module 4: F	Pharmacokinetics	
Oct 29	Pharmacokinetic Considerations in Drug Design and Development	Dr. Punit Marathe
Nov 19	Prodrugs in Drug Discovery	Dr. John Higgins